Lucitanib for the Treatment of HR+/HER2− Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study

Abstract

Lucitanib had modest antitumor activity and significant hypertension-related toxicity in patients with HR <b>⁺</b> /HER2 <b>^-</b> MBC. Although based on small sample sizes, exploratory biomarker analyses suggested that patients with high <i>FGFR1</i> amplification or expression might derive greater benefit.